Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout growth, and the company's up-and-coming products in various stages of development offer promise as well.

Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Meanwhile, Boston Scientific is still waiting for antitrust regulators to conclude their review of its proposal to buy Axonics, which was announced in January.

Strategics tend to invest in med-tech companies they are looking to acquire or could be acquired. Furthermore, companies like ...

Medtronic (NYSE: MDT) today announced the publication of its novel approach to studying adaptive deep brain stimulation (aDBS ...

Medtronic plc (NYSE: MDT) is a leading global medical device maker in the medical sector. Its innovative and critical medical ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Medtronic (MDT – Research Report), with a ...

Medtronic PLC closed $2.15 below its 52-week high ($91.49), which the company reached on September 4th.

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

The Medical Devices segment includes the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation, and diabetes care products. Latest Medical ...